CB 114
Alternative Names: CB-114Latest Information Update: 20 Apr 2022
Price :
$50 *
At a glance
- Originator Chimeron Bio
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 29 Mar 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Chimeron Bio pipeline, March 2022)